Skip to content

Epidemiology

TL;DR — Criteria-based general-population prevalence clusters near 2% (pooled 1.78%, 95% CI 1.65–1.92; Heidari 2017, PMID 28447207), but the number is criteria-dependent: in one Scottish population the ACR 1990, 2010, and modified-2010 definitions gave 1.7%, 1.2%, and 5.4% respectively (Jones 2015, PMID 25323744). The >90%-female stereotype comes from tender-point-era criteria and clinic selection; unbiased survey-criteria samples are ≈60% female (Wolfe 2018, PMID 30212526). Diagnosis lags symptoms by roughly 2–6 years (Choy 2010, PMID 20420681; Gendelman 2019, PMID 31174818), FM associates with lower education and income (White 1999, PMID 10405947), and annual healthcare costs run ~3× matched controls (Berger 2007, PMID 17655684). All-cause mortality is at most mildly elevated and absent in criteria-defined subgroups (SMR 0.90, Wolfe 2011, PMID 20662040; pooled HR 1.27, Treister-Goltzman 2023, PMID 37429737), but suicide is consistently over-represented (pooled suicide SMR 3.37; ibid). Administrative prevalence is rising steeply where measured (1.04%→3.88%, Israel 2009–2024; Treister-Goltzman 2026, PMID 42551405) — a trend confounded with diagnostic behavior.

Prevalence

Every figure below is tied to the criteria set that produced it; comparing across rows without that column is meaningless (see diagnostic criteria).

Population studies (direct ascertainment)

Population / year Criteria Prevalence (95% CI where given) Sex split Source (PMID)
Wichita, USA, 1995 (n=3,006) ACR 1990 2.0% (1.4–2.7) Women 3.4% (2.3–4.6), men 0.5% (0.0–1.0) 7818567
London, Ontario, Canada, 1999 (n=3,395) ACR 1990 3.3% (3.2–3.4) Women 4.9%, men 1.6% (~3:1) 10405947
NE Scotland, 2015 (n=1,604 surveyed) ACR 1990 / 2010 / mod-2010 head-to-head 1.7% (0.7–2.8) / 1.2% (0.3–2.1) / 5.4% (4.7–6.1) F:M 13.7:1 / 4.8:1 / 2.3:1 25323744
Germany, 2012 (n=2,445) 2011 modified (survey) 2.1% (1.6–2.7) Women 2.4%, men 1.8% (difference not significant) 23424058
USA NHIS 2012 (weighted to 225.7 M adults) Surrogate 2011-modified 1.75% (1.42–2.07) ≈ 3.94 million adults — 26379048
Olmsted County, USA, 2013 2011 survey criteria vs medical-record diagnosis 6.4% (survey; 27.6% response rate) vs 1.1% (diagnosed) Criteria-positive men rarely diagnosed 23203795

Reviews and meta-analyses

Source Scope Headline figures Source (PMID)
Queiroz 2013 review Worldwide studies by country/continent Reviews prevalence and incidence across countries; notes 2010-modified criteria enabled larger national surveys 23801009
Heidari 2017 meta-analysis 65 papers, 81 estimates, 3,609,810 subjects General population 1.78% (1.65–1.92); women 3.98% (2.80–5.20); men 0.01% (−0.04–0.06); rheumatology/internal-medicine clinic patients 15.2% (13.6–16.9); IBS 12.9%; hemodialysis 6.3%; T2DM 14.8% 28447207
Marques 2017 review update (2005–2014 studies) 39 studies General population 0.2–6.6%; women 2.4–6.8%; urban 0.7–11.4%; rural 0.1–5.2%; special populations 0.6–15% 28743363
Häuser 2015 primer Narrative synthesis Symptom prevalence 2–4% in general populations; "administrative prevalence" (actually diagnosed) much lower 27189527
Clauw 2014 review Narrative synthesis 2–8% of the population depending on criteria 24737367

The near-zero pooled male prevalence in Heidari 2017 (0.01%) sits against male prevalence of 0.5–1.8% in individual criteria studies (Wolfe 1995, PMID 7818567; White 1999, PMID 10405947; Wolfe 2013, PMID 23424058) and ≈40% male share under 2016 criteria in unbiased samples (Wolfe 2018, PMID 30212526); the discrepancy tracks which criteria dominated the pooled studies and illustrates that male FM detection is criteria- and setting-dependent. Presented as conflicting, per repository convention.

Incidence

Incidence data are thin compared with prevalence data.

Study Design Figure Source (PMID)
US insurance claims 1997–2002 (62,000 enrollees/yr) ICD-9 code 729.1, retrospective cohort Age-adjusted incidence 6.88/1000 person-years (men), 11.28/1000 person-years (women); F:M 1.64 (1.59–1.69); comorbidity ORs 2.14–7.05 for depression, anxiety, headache, IBS, CFS, SLE, RA 16755239
Norwegian women with self-reported musculoskeletal pain, 5.5-yr follow-up Prospective, ACR 1990 exam 25% (43/175 at-risk) developed FM; predictors: ≥4 associated symptoms, pain ≥6 yr, back pain, self-assessed depression 10555910
Southern Israel (Clalit), 2009–2024 Administrative cohort, ages 12–90 Incidence and prevalence both rose significantly; largest incidence increases at ages 30–59; declining in adolescents 42551405

Claims-based rates measure coding behavior as much as disease onset (code-defined cases, no criteria assessment; Weir 2006, PMID 16755239) — a caveat that applies to all administrative figures on this page.

Age and sex distribution

  • Prevalence rises with age into late middle life: highest values at 60–79 years (>7.0% in women) in Wichita (Wolfe 1995, PMID 7818567); female peak ~8% at 55–64 in Ontario, declining thereafter (White 1999, PMID 10405947).
  • Mean age among clinical survey respondents: 61% aged 36–59 (Choy 2010, PMID 20420681). In the Israeli administrative cohort, mean age at diagnosis has been falling (Treister-Goltzman 2026, PMID 42551405).
  • Sex ratio is criteria-dependent (13.7:1 → 2.3:1 across criteria sets in one population, Jones 2015, PMID 25323744) and selection-dependent (>90% female among referred/diagnosed patients vs 58.7–59.2% female among criteria-positive cases in unbiased samples, Wolfe 2018, PMID 30212526). Details in diagnostic criteria.
  • Women in criteria-positive samples carry modestly higher symptom burden than men (PSD 10.2 vs 8.2; generalized pain 36.8% vs 32.4%) (Wolfe 2018, PMID 30212526).

Diagnostic delay

Cohort Delay Source (PMID)
800 diagnosed patients, 6 European countries + Mexico + South Korea (2010) ~1 year from symptom onset to first presentation, then mean 2.3 years and 3.7 physicians to diagnosis; mean symptom duration 6.5 years at survey 20420681
3,434 diagnosed patients, Israeli HMO claims (2008–2011) Mean 6.42 years (SD 3.57) from first characteristic complaints to diagnosis; longer with comorbidity, younger patient age, older physician age; a characteristic complaint pattern preceded diagnosis in 67.9% of cases vs 27.6% of controls 31174818

Delay has a measurable cost side: in UK primary-care data, being given the diagnosis bent the cost curve downward — average saving £66.21 per patient per 6 months over 4 years post-diagnosis, mostly from fewer tests, imaging, drugs, and GP visits (Annemans 2008, PMID 18311794). Under-diagnosis at population scale (73% of criteria-positive undiagnosed; Walitt 2015, PMID 26379048) implies this inefficiency is widespread.

Socioeconomic gradients

  • Ontario: FM associated with female sex, middle age, less education, lower household income, being divorced, and being disabled (White 1999, PMID 10405947).
  • US NHIS: criteria-positive status associated with sex, education, ethnicity, citizenship, and unhealthy behaviors; caseness predicted by demographics, behaviors, and comorbidity (Walitt 2015, PMID 26379048).
  • Norwegian at-risk cohort: lack of formal education weakly associated with FM development in women with limited pain (Forseth 1999, PMID 10555910).
  • No adequately powered study of income/education gradients using post-2016 criteria was located in this review [unverified gap, not a verified absence].

Healthcare utilization and costs

Study Setting Figures Source (PMID)
Wolfe 1997 (7-yr prospective, 538 patients, 6 US rheumatology centers) US clinic ~10 outpatient visits/yr (≈1/month counting nontraditional care); 1 hospitalization per 3 years; mean 2.7 FM drugs per 6 months; mean yearly cost $2,274 (1996 USD), right-skewed 9324009
Berger 2007 (claims, 33,176 FM patients vs matched controls) US insurance Total 12-month costs $9,573 vs $3,291 (mean; ~3×); median $4,247 vs $822 (~5×); more comorbidity and pain-related pharmacotherapy (65% vs 34%) 17655684
D'Onghia 2022 (systematic review, 36 studies) Multinational Total direct annual costs per patient $1,750–$35,920 (USA) and $1,250–$8,504 (Europe), 2019 USD; medications the largest driver in most studies; high risk of bias overall 35849890
Annemans 2008 (UK primary-care records) UK NHS (excl. hospital) Diagnosis followed by cost reduction vs predicted trend (−£66.21/6 months/patient over 4 yr) 18311794
Treister-Goltzman 2026 (Israel 2009–2024) Administrative Shift toward fewer hospitalizations/specialist visits but more imaging; rising pregabalin/duloxetine/gabapentin, falling amitriptyline/NSAIDs; opioids rose to 2019–2020 then fell 42551405

Disability and work loss

  • 22% of surveyed patients unable to work at all and 25% unable to work consistently because of FM (Choy 2010, PMID 20420681).
  • US criteria-positive persons show high self-reported pain, comorbidity, psychological distress, medical costs, Social Security and work disability (Walitt 2015, PMID 26379048).
  • FM patients show high lifetime surgical rates (back/neck surgery, appendectomy, carpal tunnel, gynecologic, abdominal surgery) relative to other rheumatic disease patients (Wolfe 1997, PMID 9324009).
  • Indirect costs (productivity loss) are a major component of the economic burden beyond the direct costs tabled above (D'Onghia 2022, PMID 35849890).

Mortality and suicide

Report both signals; they differ.

All-cause mortality — weak or null:

  • 8,186 US patients, 35 years, 539 deaths: SMR 0.90 (95% CI 0.61–1.26); vs osteoarthritis controls HR 1.05 (0.94–1.17) (Wolfe 2011, PMID 20662040).
  • 1,361 Danish referred patients: no overall increase in mortality (Dreyer 2010, PMID 20583101).
  • Chronic-pain systematic review (10 studies, includes widespread pain/FM; 7 pooled): MRR 1.14 (0.95–1.37), non-significant, high heterogeneity (Smith 2014, PMID 24901358).
  • FM-specific meta-analysis (8 studies, 188,751 patients): all-cause HR 1.27 (1.04–1.51) — but not elevated in the subgroup diagnosed by 1990 criteria; cancer mortality lower (SMR 0.82, 0.69–0.97); infection mortality higher (SMR 1.66, 1.15–2.38); accidents borderline (SMR 1.95, 0.97–3.92); significant heterogeneity (Treister-Goltzman 2023, PMID 37429737).

Suicide — consistently elevated:

  • Suicide OR 3.31 (2.15–5.11) and accidental-death OR 1.45 (1.02–2.06) vs US population (Wolfe 2011, PMID 20662040).
  • Danish women: suicide SMR 10.5 (4.5–20.7), elevated at diagnosis and still after 5 years; also liver cirrhosis/biliary disease SMR 6.4 and cerebrovascular SMR 3.1; no increased cause-specific mortality in the 84 men (Dreyer 2010, PMID 20583101).
  • Pooled suicide SMR 3.37 (1.52–7.50) (Treister-Goltzman 2023, PMID 37429737).
  • Suicidality meta-analysis (13 studies, 394,087 patients): suicidal ideation prevalence 29.57% (95% CI 1.84–72.07), OR 9.12 (1.42–58.77); attempts 5.69% (1.26–31.34), OR 3.12 (1.37–7.12); suicide events HR 1.38 (1.17–1.71). Caveats stated by the authors: high heterogeneity, publication-bias evidence, and loss of significance in some analyses after adjusting for psychiatric comorbidity (Adawi 2021, PMID 34867495).

Interpretation: the mortality excess, where present, concentrates in suicide (and possibly accidents and infections), not disease-specific organ failure; whether suicide risk is attributable to FM itself or to comorbid depression/anxiety is unresolved (Dreyer 2010, PMID 20583101; Adawi 2021, PMID 34867495) — see comorbidities and overlap.

  • Southern Israel, 2009–2024: diagnosed prevalence 1.04% → 3.88%; incidence up most at ages 30–59, down in adolescents; male share rising; mean diagnosis age falling; psychiatric comorbidity (anxiety, depression, PTSD) rising while total comorbidity burden stable (Treister-Goltzman 2026, PMID 42551405).
  • Criteria eras mechanically shift measured prevalence and case mix (1.7%→5.4% within one population depending on definition; Jones 2015, PMID 25323744), so any temporal trend in diagnosed FM confounds disease dynamics with definitional and diagnostic-behavior change (Wolfe & Walitt 2013, PMID 23820862).
  • The persistent gap between criteria-positive and diagnosed populations (Walitt 2015, PMID 26379048; Vincent 2013, PMID 23203795) means administrative prevalence can rise for years on recognition alone without any change in underlying symptom prevalence [interpretive synthesis of the cited studies].

Open questions

  • Is true (criteria-based) prevalence changing over time anywhere? All demonstrated trends are administrative (Treister-Goltzman 2026, PMID 42551405); no repeated criteria-based population survey with constant methods was located.
  • What is the population incidence under 2016 criteria? Existing incidence numbers are claims-based (Weir 2006, PMID 16755239) or from selected at-risk women (Forseth 1999, PMID 10555910).
  • Does earlier diagnosis change outcomes or only costs? The cost benefit is documented (Annemans 2008, PMID 18311794); clinical-outcome benefit of shortening the 2–6-year delay (Choy 2010, PMID 20420681; Gendelman 2019, PMID 31174818) is not.
  • Is the suicide excess modifiable by FM treatment, or is it fully mediated by psychiatric comorbidity? Adjusted analyses lose significance inconsistently (Adawi 2021, PMID 34867495).
  • Why is cancer mortality lower in FM cohorts (SMR 0.82; Treister-Goltzman 2023, PMID 37429737) — surveillance artifact, selection, or biology?
  • What are prevalence and burden in low- and middle-income countries under modern criteria? Regional coverage in existing reviews is uneven (Queiroz 2013, PMID 23801009; Marques 2017, PMID 28743363).

References

  1. Heidari F, et al. Prevalence of fibromyalgia in general population and patients, a systematic review and meta-analysis. Rheumatol Int. 2017;37(9):1527-1539. PMID 28447207
  2. Jones GT, et al. The prevalence of fibromyalgia in the general population: a comparison of the ACR 1990, 2010, and modified 2010 classification criteria. Arthritis Rheumatol. 2015;67(2):568-75. PMID 25323744
  3. Wolfe F, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38(1):19-28. PMID 7818567
  4. White KP, et al. The London Fibromyalgia Epidemiology Study: the prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol. 1999;26(7):1570-6. PMID 10405947
  5. Wolfe F, et al. Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population. Arthritis Care Res (Hoboken). 2013;65(5):777-85. PMID 23424058
  6. Walitt B, et al. The Prevalence and Characteristics of Fibromyalgia in the 2012 National Health Interview Survey. PLoS One. 2015;10(9):e0138024. PMID 26379048
  7. Vincent A, et al. Prevalence of fibromyalgia: a population-based study in Olmsted County, Minnesota, utilizing the Rochester Epidemiology Project. Arthritis Care Res (Hoboken). 2013;65(5):786-92. PMID 23203795
  8. Queiroz LP. Worldwide epidemiology of fibromyalgia. Curr Pain Headache Rep. 2013;17(8):356. PMID 23801009
  9. Marques AP, et al. Prevalence of fibromyalgia: literature review update. Rev Bras Reumatol Engl Ed. 2017;57(4):356-363. PMID 28743363
  10. Häuser W, et al. Fibromyalgia. Nat Rev Dis Primers. 2015;1:15022. PMID 27189527
  11. Clauw DJ. Fibromyalgia: a clinical review. JAMA. 2014;311(15):1547-55. PMID 24737367
  12. Wolfe F, et al. Fibromyalgia diagnosis and biased assessment: Sex, prevalence and bias. PLoS One. 2018;13(9):e0203755. PMID 30212526
  13. Weir PT, et al. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on ICD-9 codes. J Clin Rheumatol. 2006;12(3):124-8. PMID 16755239
  14. Forseth KO, et al. Prognostic factors for the development of fibromyalgia in women with self-reported musculoskeletal pain. A prospective study. J Rheumatol. 1999;26(11):2458-67. PMID 10555910
  15. Treister-Goltzman Y. Trends in incidence, patient characteristics, healthcare use, and medication in fibromyalgia: A large Israeli cohort study. Semin Arthritis Rheum. 2026;80:153046. PMID 42551405
  16. Choy E, et al. A patient survey of the impact of fibromyalgia and the journey to diagnosis. BMC Health Serv Res. 2010;10:102. PMID 20420681
  17. Gendelman O, et al. Time to diagnosis of fibromyalgia and factors associated with delayed diagnosis in primary care. Best Pract Res Clin Rheumatol. 2019;32(4):489-499. PMID 31174818
  18. Annemans L, et al. Health economic consequences related to the diagnosis of fibromyalgia syndrome. Arthritis Rheum. 2008;58(3):895-902. PMID 18311794
  19. Wolfe F, et al. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum. 1997;40(9):1560-70. PMID 9324009
  20. Berger A, et al. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract. 2007;61(9):1498-508. PMID 17655684
  21. D'Onghia M, et al. The economic burden of fibromyalgia: A systematic literature review. Semin Arthritis Rheum. 2022;56:152060. PMID 35849890
  22. Wolfe F, et al. Mortality in fibromyalgia: a study of 8,186 patients over thirty-five years. Arthritis Care Res (Hoboken). 2011;63(1):94-101. PMID 20662040
  23. Dreyer L, et al. Mortality in a cohort of Danish patients with fibromyalgia: increased frequency of suicide. Arthritis Rheum. 2010;62(10):3101-8. PMID 20583101
  24. Smith D, et al. Chronic pain and mortality: a systematic review. PLoS One. 2014;9(6):e99048. PMID 24901358
  25. Treister-Goltzman Y, Peleg R. Fibromyalgia and mortality: a systematic review and meta-analysis. RMD Open. 2023;9(3):e003005. PMID 37429737
  26. Adawi M, et al. Suicidal Behavior in Fibromyalgia Patients: Rates and Determinants of Suicide Ideation, Risk, Suicide, and Suicidal Attempts — A Systematic Review of the Literature and Meta-Analysis of Over 390,000 Fibromyalgia Patients. Front Psychiatry. 2021;12:629417. PMID 34867495
  27. Wolfe F, Walitt B. Culture, science and the changing nature of fibromyalgia. Nat Rev Rheumatol. 2013;9(12):751-5. PMID 23820862